Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Doxorubicin in cTACE for Liver Cancer
NCT02753881Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2015
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin in liver cancer (2 arms), sponsored by Yale University. Primary endpoints: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized), Pharmacokinetics Profile-- Peak of Plasma Concentration and 3 more. Started Nov 2015; status: completed.
02
Drugs
doxorubicin
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT02753881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753881.